Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. | |
| Pfizer Announces Neratinib Data In HER2 Positive Breast Cancer (Business Wire) December 12, 2009 at 6:30 pm |
| SAN ANTONIO----Pfizer Inc. today announced results from studies evaluating neratinib , an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium . | | |
No comments:
Post a Comment